- Home
- CAPL vs STOK Comparison
CAPL vs STOK Comparison
Compare CAPL & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPL
- STOK
- Stock Information
- Founded
- CAPL 1992
- STOK 2014
- Country
- CAPL United States
- STOK United States
- Employees
- CAPL N/A
- STOK N/A
- Industry
- CAPL Oil Refining/Marketing
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- CAPL Energy
- STOK Health Care
- Exchange
- CAPL Nasdaq
- STOK Nasdaq
- Market Cap
- CAPL 788.6M
- STOK 740.9M
- IPO Year
- CAPL 2012
- STOK 2019
- Fundamental
- Price
- CAPL $21.60
- STOK $12.91
- Analyst Decision
- CAPL
- STOK Strong Buy
- Analyst Count
- CAPL 0
- STOK 5
- Target Price
- CAPL N/A
- STOK $27.75
- AVG Volume (30 Days)
- CAPL 27.7K
- STOK 787.2K
- Earning Date
- CAPL 08-06-2025
- STOK 08-15-2025
- Dividend Yield
- CAPL 9.74%
- STOK N/A
- EPS Growth
- CAPL 30.34
- STOK N/A
- EPS
- CAPL 0.80
- STOK 0.88
- Revenue
- CAPL $3,694,780,000.00
- STOK $190,908,000.00
- Revenue This Year
- CAPL N/A
- STOK $409.12
- Revenue Next Year
- CAPL N/A
- STOK N/A
- P/E Ratio
- CAPL $27.05
- STOK $14.74
- Revenue Growth
- CAPL N/A
- STOK 2333.81
- 52 Week Low
- CAPL $18.43
- STOK $5.35
- 52 Week High
- CAPL $25.73
- STOK $16.15
- Technical
- Relative Strength Index (RSI)
- CAPL 52.17
- STOK 55.96
- Support Level
- CAPL $20.30
- STOK $12.25
- Resistance Level
- CAPL $22.41
- STOK $13.12
- Average True Range (ATR)
- CAPL 0.53
- STOK 0.86
- MACD
- CAPL 0.08
- STOK -0.06
- Stochastic Oscillator
- CAPL 59.36
- STOK 37.50
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.